Advanced Filters
noise

Pneumonia Clinical Trials

A listing of Pneumonia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,326 clinical trials
P Pellegrino Musto

Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context

Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed/Refractory

18 years of age All Phase N/A
A Ambroise MARCAIS, MD

Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)

The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1 chronically infected patients with / without extra-haematological disorders (cohort 2).

18 years of age All Phase N/A

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or …

years of age All Phase N/A
P Philipp B. Staber, MD, PhD

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

18 years of age All Phase N/A

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

This will be a multicenter, national, non-interventional, prospective cohort study

- 100 years of age All Phase N/A
J J. Nuver, MD, PhD

Early Ageing During Therapy in AYA Cancer Patients

Longitudinal cohort study; measurements before start of systemic therapy and one year later.

18 - 39 years of age All Phase N/A
B Brigit Lapolla

Tissue Repository: CTCL Collection Protocol

This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL). The purpose of this study is to establish a protocol for the collection and storage of tissue samples …

18 years of age All Phase N/A
J Julian A Luetkens, PD Dr.

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syndrome, which has been described to lead to myocarditis, but larger studies exploring this relationship are currently lacking. …

18 years of age All Phase N/A
C Clinical Trial Referral Office

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).

2 - 22 years of age All Phase N/A
C Courtney Schepel

Pre-malignant States to Hematologic Malignancies in Firefighters

The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.

40 - 49 years of age All Phase N/A

Simplify language using AI